H-(D)-Phe-(D)-Phe-NH2 | 138848-39-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: H-(D)-Phe-(D)-Phe-NH2
• 英文别名: (D)-Phe-(D)-Phe-NH2；(2R)-2-amino-N-[(2R)-1-amino-1-oxo-3-phenylpropan-2-yl]-3-phenylpropanamide
• CAS: 138848-39-2
• 化学式: C₁₈H₂₁N₃O₂
• 分子量: 311.384
• InChiKey: XXPXQEQOAZMUDD-HZPDHXFCSA-N

物化性质

• 沸点：
  620.7±55.0 °C(Predicted)
• 密度：
  1.196±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  98.2
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  Fmoc-D-苯丙氨酸 在 哌啶 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以38%的产率得到H-(D)-Phe-(D)-Phe-NH2
  参考文献：
  名称：

  Discovery of Dipeptides with High Affinity to the Specific Binding Site for Substance P₁₋₇

  摘要：

  Substance P 1-7 (SP1-7, H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-OH) is the major bioactive metabolite of substance P. The interest in this heptapeptide originates from the observation that it modulates, and in certain cases opposes the effects of the parent peptide. e.g., the nociceptive effect. The p-opioid receptor agonist endomorphin-2 (EM-2, H-Tyr-Pro-Phe-Phe-NH2) has been found to also interact with the specific binding site of SP1-7 with only a 10-fold lower affinity compared to the native peptide. Considering the smaller size of EM-2 compared to the target heptapeptide, it was selected as a lead compound in the development of low-molecular-weight ligands to the SP1-7 binding site. An alanine scan and truncation study led to the unexpected discovery of the dipeptide H-Phe-Phe-NH2 (K-i = 1.5 nM), having equal affinity as the endogenous heptapeptide SP1-7. Moreover, the studies show that the C-terminal phenylalanine amide is crucial for the affinity of the dipeptide.

  DOI：

  10.1021/jm901352b

文献信息

• Radiopharmaceuticals, radioimaging agents, and uses thereof
  申请人：Clarity Pharmaceuticals Ltd

  公开号：US10975089B2

  公开（公告）日：2021-04-13

  The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.

  本发明涉及可用作放射性药物和放射性成像剂的带有放射性核素螯合剂的化合物。这些配位化合物可用于放射治疗和诊断成像。本发明还涉及利用本发明的非配位化合物和放射性标记化合物进行诊断、预后和治疗的方法。
• [EN] PEPTIDE AMIDE SALT, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE<br/>[FR] SEL D'AMIDE PEPTIDIQUE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION EN MÉDECINE<br/>[ZH] 一种肽酰胺盐及其制备方法和在医药上的用途
  申请人：SICHUAN HAISCO PHARMACEUTICAL CO LTD

  公开号：WO2021013085A1

  公开（公告）日：2021-01-28

  一种通式(I)所示的化合物或其立体异构体、制备方法和在医药上的用途，通式(I)如下所示，各取代基的定义与说明书中一致。